Dr. Ajroud-Driss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
259 E Erie St
Chicago, IL 60611Phone+1 312-695-7950Fax+1 312-695-5747
Education & Training
University of Illinois College of Medicine at ChicagoResidency, Neurology, 2001 - 2004
National School of Science - Tunisia Faculty of MedicineClass of 1996
McGaw Medical Center of Northwestern UniversityFellowship, Neuromuscular Medicine (Neurology)
Certifications & Licensure
IL State Medical License 2003 - 2026
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- International Guillain-Barré Syndrome Outcome Study Start of enrollment: 2012 May 01
- Weekly Steroids in Muscular Dystrophy Start of enrollment: 2019 Jul 01
Publications & Presentations
PubMed
- Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial., Jinsy Andrews, Sabrina Paganoni, Eric A Macklin, Lori B Chibnik
JAMA Neurology. 2025-02-17 - 2 citationsCNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., James D Berry, Nicholas J Maragakis, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17 - Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., Jeremy M Shefner, Björn Oskarsson, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17
Press Mentions
Sean M. Healey & AMG Center Announces Update in ALS Platform Trial with FosigotifatorJanuary 6th, 2025- Advocating to Fight ALSSeptember 21st, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
